Pulmonary Drugs Market, by Drug Class (Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, and Others), by Application (Asthma & COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce), and by Region - Global Trends, and Forecast till 2025

  • Published On : Feb 2018 |
  • Pages : 304 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Pulmonary Drugs Market – Boon for Diseased Lungs

Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated with the help of appropriate medication. This has led to intensification of efforts for development of effective and efficient pulmonary drugs and medications. Some of the pulmonary drugs are administered with the help of devices called nebulizers or inhalers.

The global pulmonary drugs market was valued at US$ 28.1 billion in 2016 and is expected to witness a robust CAGR of 8.1% over the forecast period (2017 - 2025).

Figure 1. Global Pulmonary Drugs Market (US$ Mn), by Region, 2016

pulmonary drugs market

Source: Coherent Market Insights (2018) 

Increasing tobacco smoking to augment market growth

Increasing incidence of Chronic Obstructive Pulmonary Disease (COPD) is directly proportional to the tobacco smoking and exposure. According to the World Health Organization (WHO) 2016, tobacco smoking is the primary cause of COPD leading to around 90% of COPD cases. The irreversible damages caused due to smoke leads to adoption of lifestyle adjustments and medical treatments that includes consumption of bronchodilators, inhaled glucocorticoids, inhaled steroids, and other pulmonary drugs to relieve the disease symptoms, thereby propelling demand for pulmonary drugs. Tobacco is major cause of death and illness across the world. The number of smokers is consistent globally and does not have a drop since a past few years. Smokers are highly susceptible to respiratory diseases such as COPD and asthma. For instance, according to the Centers of Disease Control and Prevention (CDC) the average rate of smokers in 2012 was 1 in 5 people, which was reported to be constant in the Burden of Tobacco use in the U.S. released in 2015. North America dominates the global pulmonary drugs market, owing to the increasing prescriptions of Inhaled corticosteroids (ICS) and Long-acting beta-agonists (LABA) combinational products. According to Ontario Drug Policy Research Network, 2015, ICS+LABA combination products are the second-most commonly prescribed inhaled respiratory medications for all indications in Canada, with 1.1 million prescriptions dispensed in the fourth quarter of 2013, whereas, short-acting beta-agonists (e.g., salbutamol) are the most frequently prescribed inhaled respiratory medications in Canada with 1.8 million prescriptions dispensed in the same time period.

Supportive government and non-government initiatives to accelerate the market growth  

The government and non-government initiatives help patients to fight the diseases by providing sufficient medical care and education regarding the benefits of preventive measures as well as appropriate medications to curb the life threatening diseases such as COPD. For instance, in 2016, according to the World Health Organization (WHO), more than 90% of deaths were reported due to COPD in low and middle-income economies. Thus, the WHO initiated Global Alliance against Chronic Respiratory Diseases (GARD) with a vision to provide required medical treatments to patients suffering from chronic respiratory diseases in low and middle income economies. This provision demands a significant quantity of medication that is expected to propel the pulmonary drugs market. Also, in 2015, the Bill and Melinda Gates Foundation granted a US$ 89 Mn funding to Novavax, to develop RSV F (Respiratory Syncytial Virus) Vaccine for pregnant women in low sourced countries as maternal immunization vaccine to protect respiratory infections in the children. Asia Pacific is expected to be the fastest growing region in the pulmonary drugs market, owing to the continuous marketing of new brands to consolidate and strengthen the sales of products by the manufacturers. For instance, in 2016, Lupin Limited and Novartis Healthcare Private Limited (NHPL) entered into a co-marketing agreement to promote Novartis’s Indacaterol / Glycopyrronium inhaler in India for treating COPD under the brand name of Loftair. The major players operating the global pulmonary drugs market include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZenca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici S.p.A., Zambon Company S.p.A., Alaxia SAS, and Merck Sharp & Dohme Limited.

The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.

Market Dynamics

The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives. According to Center for Disease Control and Prevention (CDC), in 2015, 25 million people in the U.S. suffered from asthma that is 1 in 13 Americans were suffering from asthma. Under 18 years of age, 6.2 million people suffered from asthma. Annually asthma accounts for 14.2 million physician office visits and 1.8 million emergency visits. Moreover, the significant number of patent expiration of branded drugs, funding for research and development and launch of innovative products are expected to contribute as major factors in the market growth over the forecast period. For instance, in 2017, GSK received U.S. FDA approval for unique three-in-one inhaler named Trelegy Ellipta for chronic lung disease. Trelegy Ellipta combines three therapies into a single inhaler, thereby giving a new treatment option to the patients. However, a large undiagnosed population and side effects associated with the consumption of these drugs resulting into kidney problems leading to adverse outcomes are expected to limit the market growth.  

Key features of the study:

  • This report provides in-depth analysis of pulmonary drugs market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global pulmonary drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceuticals S.p.A, Zambon Company S.p.A, Alaxia SAS, and Merck Sharp & Dohme Limited
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global pulmonary drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pulmonary drugs market

Detailed Segmentation:

  • Global Pulmonary Drugs Market, By Drug Class:
    • Inhaled Corticosteroids
    • Long Acting Beta-2 Agonists
    • Antihistamines
    • Vasodilators
    • Short Acting Beta-2 Agonists
    • Others
  • Global Pulmonary Drugs Market, By Application:
    • Asthma & COPD
    • Allergic Rhinitis
    • Pulmonary Arterial Hypertension
    • Cystic Fibrosis
    • Others
  • Global Pulmonary Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • E-Commerce
  • Global Pulmonary Drugs Market, By Geography:
    • North America
      • By Drug Class:
        • Inhaled Corticosteroids
        • Long Acting Beta-2 Agonists
        • Antihistamines
        • Vasodilators
        • Short Acting Beta-2 Agonists
        • Others
      • By Application:
        • Asthma & COPD
        • Allergic Rhinitis
        • Pulmonary Arterial Hypertension
        • Cystic Fibrosis
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • E-Commerce
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Class:
        • Inhaled Corticosteroids
        • Long Acting Beta-2 Agonists
        • Antihistamines
        • Vasodilators
        • Short Acting Beta-2 Agonists
        • Others
      • By Application:
        • Asthma & COPD
        • Allergic Rhinitis
        • Pulmonary Arterial Hypertension
        • Cystic Fibrosis
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • E-Commerce
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class:
        • Inhaled Corticosteroids
        • Long Acting Beta-2 Agonists
        • Antihistamines
        • Vasodilators
        • Short Acting Beta-2 Agonists
        • Others
      • By Application:
        • Asthma & COPD
        • Allergic Rhinitis
        • Pulmonary Arterial Hypertension
        • Cystic Fibrosis
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • E-Commerce
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class:
        • Inhaled Corticosteroids
        • Long Acting Beta-2 Agonists
        • Antihistamines
        • Vasodilators
        • Short Acting Beta-2 Agonists
        • Others
      • By Application:
        • Asthma & COPD
        • Allergic Rhinitis
        • Pulmonary Arterial Hypertension
        • Cystic Fibrosis
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • E-Commerce
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
        • Inhaled Corticosteroids
        • Long Acting Beta-2 Agonists
        • Antihistamines
        • Vasodilators
        • Short Acting Beta-2 Agonists
        • Others
      • By Application:
        • Asthma & COPD
        • Allergic Rhinitis
        • Pulmonary Arterial Hypertension
        • Cystic Fibrosis
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • E-Commerce
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class:
        • Inhaled Corticosteroids
        • Long Acting Beta-2 Agonists
        • Antihistamines
        • Vasodilators
        • Short Acting Beta-2 Agonists
        • Others
      • By Application:
        • Asthma & COPD
        • Allergic Rhinitis
        • Pulmonary Arterial Hypertension
        • Cystic Fibrosis
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • E-Commerce
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Sanofi SA*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Meda Pharmaceuticals
    • Circassia Pharmaceuticals Plc.
    • AstraZeneca Plc.
    • GlaxoSmithKline Plc.
    • Mallinckrodt Pharmaceuticals Plc.
    • Cheisi Farmaceutici S.p.A
    • Zambon Company S.p.A
    • Alaxia SAS
    • Merck Sharp & Dohme Limited

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Application
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • Regulatory Scenario
    • Pipeline Analysis
    • Promotional Activities and Campaigns
    • Supply Chain Analysis
    • PEST Analysis
    • Epidemiology
  4. Global Pulmonary Drugs Market, By Drug Class, 2017 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017 – 2025
      • Segment Trends
    • Inhaled Corticosteroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Long Acting Beta-2 Agonists
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Antihistamines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Vasodilators
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Short Acting Beta-2 Agonists
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
  5. Global Pulmonary Drugs Market, By Application, 2017 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017 – 2025
      • Segment Trends
    • Asthma & COPD
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Allergic Rhinitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Pulmonary Arterial Hypertension
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Cystic Fibrosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
  6. Global Pulmonary Drugs Market, By Distribution Channel, 2017 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017 – 2025
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • E-Commerce
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
  7. Global Pulmonary Drugs Market, By Region, 2017 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017 – 2025
    • North America
      • Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • Brazil
        • Mexico
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of APAC
    • Middle East
      • Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis (3x3 Matrix)
    • Company Profiles
      • Sanofi SA*
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Meda Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Circassia Pharmaceuticals Plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • AstraZeneca Plc.
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • GlaxoSmithKline Plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Mallinckrodt Pharmaceuticals Plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Cheisi Farmaceutici S.p.A
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Zambon Company S.p.A
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Alaxia SAS
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Merck Sharp & Dohme Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 50 market data tables and 38 figures on "Pulmonary Drugs Market - Global forecast to 2025”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.